Catalio Capital Management (Catalio), a multi-strategy life sciences investment firm, has launched a Credit Opportunities strategy to expand the scope of the firm’s investments across the biomedical technology industry and meet the growing demand for non-dilutive growth capital within the sector.

The Catalio Credit Opportunities strategy seeks to provide senior-secured structured credit to breakthrough biomedical companies, targeting well-capitalised, pre-cashflow businesses with significant support from institutional investors. The strategy will be led by Co-Portfolio Managers John Henry Iucker and Robert Snyder. Iucker and Snyder both joined Catalio from Brown Advisory, an asset management firm with over USD100 billion in AUM, where they played an instrumental role in building Brown’s credit platform.

In addition to Iucker and Snyder, Joshua Samuelson will be joining the Investment Committee of the Credit Opportunities strategy. Samuelson was a Co-Founder of PointState Capital, a long/short equity and macro-focused fund. At PointState, Samuelson served as President and managed a diverse portfolio across multiple asset classes until his retirement at the end of 2019. Prior to his time at PointState, he was a Portfolio Manager at Duquesne Capital Management and Soros Fund Management, where, over the course of his career, he focused on convertible bonds, equities and credit.

Catalio also announced today the appointment of Brandon Matz as the firm’s Head of Marketing & Investor Relations. Matz is joining Catalio from York Capital Management, a global alternative investment firm with approximately USD20 billion in AUM.

The launch of the Catalio Credit Opportunities strategy is the latest milestone of many for Catalio, which has grown exponentially since its inception last year. It is now a leading multi-strategy investment firm, with over USD450 million in committed capital between both private and public equity strategies.

George Petrocheilos and Dr Jacob Vogelstein, Catalio’s Co-Founders & Co-Managing Partners, say: “We are delighted to welcome John Henry, Rob, Josh and Brandon to Catalio. The life sciences industry continues to offer significant opportunities for investment, and these latest additions to our team will further augment our platform and help our transformative biomedical technology companies to bring their innovations to market.”


Source: Private Equity Wire